Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.93 |
| ▸ | ABL1 | P00519 | 2/20 | 0.93 |
| ▸ | ABL2 | P42684 | 2/20 | 0.93 |
| ▸ | FBP1 | P09467 | 10/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | SYK | P43405 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | GALR2 | O43603 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | VCP | P55072 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | LCK | P06239 | 3/20 | 0.61 |
| ▸ | NQO2 | P16083 | 1/20 | 0.58 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.52 |
| ▸ | RGS12 | O14924 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3667079 | 1.00 | EGFR (0.93) | EGFRABL1ABL2FBP1ALDH1A1 | |
| SCHEMBL2052283 | 0.96 | EGFR (1.00) | EGFRABL1ABL2FBP1ALDH1A1 | |
| SCHEMBL2052285 | 0.96 | EGFR (1.00) | EGFRABL1ABL2FBP1ALDH1A1 | |
| SCHEMBL29371330 | 0.96 | EGFR (1.00) | EGFRABL1ABL2FBP1ALDH1A1 | |
| SCHEMBL3672518 | 0.82 | PTGS2 (0.75) | EGFRABL1ABL2FBP1ALDH1A1 | |
| SCHEMBL3672520 | 0.82 | PTGS2 (0.75) | EGFRABL1ABL2FBP1ALDH1A1 | |
| SCHEMBL11239202 | 0.81 | EGFR (0.72) | EGFRABL1ABL2FBP1ALDH1A1 | |
| SCHEMBL13773077 | 0.81 | EGFR (0.72) | EGFRABL1ABL2FBP1ALDH1A1 | |
| SCHEMBL8012584 | 0.81 | EGFR (0.72) | EGFRABL1ABL2FBP1ALDH1A1 | |
| SCHEMBL8010045 | 0.81 | EGFR (0.72) | EGFRABL1ABL2FBP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4425628-B2 | — | — | 2010-03-03 | — | — | JP | claimed |
| EP-1435894-A4 | CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS | GALILEO PHARMACEUTICALS INC (US) | 2005-07-06 | — | — | EP | claimed |
| JP-2005505519-A | — | — | 2005-02-24 | — | — | JP | claimed |
| EP-1435894-A2 | CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS | Galileo Pharmaceuticals, Inc. (US) | 2004-07-14 | — | — | EP | claimed |
| US-20030073712-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | 2003-04-17 | — | — | US | claimed |
| WO-2003009807-A2 | CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS | GALILEO LABORATORIES, INC. (US) | 2003-02-06 | — | — | WO | claimed |
| US-7629375-B2 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629375-B2 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629375-B2 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20060178356-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | GALILEO PHARMACEUTICALS, INC. | 2006-08-10 | — | — | US | disclosed |
| EP-1435894-A4 | CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS | GALILEO PHARMACEUTICALS INC (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20050142155-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | JOHNSON & JOHNSON CONSUMER INC. | 2005-06-30 | — | — | US | disclosed |
| US-20050113416-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | GALILEO PHARMACEUTICALS, INC. | 2005-05-26 | — | — | US | disclosed |
| EP-1435894-A2 | CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS | Galileo Pharmaceuticals, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| US-20030073712-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | 2003-04-17 | — | — | US | disclosed |
| WO-2003009807-A2 | CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS | GALILEO LABORATORIES, INC. (US) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050142155-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | HSF1, HMOX1, NQO1 | EGFR 3617/4885ABL1 4324/4885ABL2 4428/4885 |
| US-20030073712-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | HSF1, HMOX1, NQO1 | EGFR 3617/4885ABL1 4324/4885ABL2 4428/4885 |
| US-20050113416-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | HSF1, HMOX1, NQO1 | EGFR 3617/4885ABL1 4324/4885ABL2 4428/4885 |
| US-20060178356-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | HSF1, HMOX1, NQO1 | EGFR 3617/4885ABL1 4324/4885ABL2 4428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.